FDA panel backs wider access to six peptide therapies amid compounding debate

FDA panel peptide therapies compounding pharmacies SAFE Drugs Act GLP-1 products

The Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) narrowly voted to recommend adding six of seven reviewed peptides—BPC‑157, TB‑500, KPV, MOTS‑c, Semax and Epitalon—to the agency’s 503A Bulks List. The advisory vote does not automatically change the legal status of the peptides and will require formal FDA rulemaking. Proponents say the move could pull patients out of the unregulated grey market of online peptide vendors.

Health and Human Services Secretary Robert F. Kennedy Jr., a self‑described “big fan” of peptides, has publicly backed the review, while bioethicist Ezekiel Emanuel criticized the panel’s endorsement as a potential health risk. More than 1,900 public comments were submitted in support of peptide access ahead of the meeting.

In parallel, the SAFE Drugs Act advanced out of the Senate HELP Committee, proposing expanded FDA authority over compounding facilities, including mandatory reporting, inspections and limits on the number of drug copies produced each month. A recent JAMA Health Forum study found that compounded GLP‑1 products remain widely available despite a 2025 shortage ending and a legal prohibition. The FDA also proposed permanently removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, further tightening large‑scale outsourcing of these weight‑loss drugs.

Entities

BPC‑157, TB‑500, KPV, MOTS‑c, Semax, Epitalon · Ezekiel Emanuel · FDA Pharmacy Compounding Advisory Committee · Food and Drug Administration · Marty Makary · Michael DiStefano · Pharmacy Compounding Advisory Committee · Robert F. Kennedy Jr. · SAFE Drugs Act · Semaglutide · U.S. Food and Drug Administration · U.S. Food and Drug Administration (FDA)

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] The SAFE Drugs Act advanced out of the Senate HELP Committee to give the FDA greater authority over compounding facilities, including mandatory reporting, inspections, and limits on monthly drug “copy nam.org
[● 4 SOURCES] The FDA panel’s vote is advisory and does not automatically change the legal status of the peptides. natlawreview.com · uinterview.com · nemosnewsnetwork.com · amgreatness.com
[● 2 SOURCES] The FDA proposed permanently removing semaglutide, tirzepatide and liraglutide from the 503B bulks list. www.clinicalnutritioncenter.com · www.medicaldaily.com
[● 3 SOURCES] The six peptides recommended are BPC‑157 for ulcerative colitis, TB‑500 and KPV for wound healing, MOTS‑c for obesity and osteoporosis, Semax for cerebral ischemia, migraine and trigeminal neuralgia, nemosnewsnetwork.com · amgreatness.com · natlawreview.com
[○ 1 SOURCE] Compounded GLP‑1 products remain widely available despite the prohibition after the 2025 shortage ended. nam.org
[● 2 SOURCES] The FDA received over 1,900 public comments supporting peptide access before the advisory panel meeting. uinterview.com · www.agencyiq.com
[● 5 SOURCES] The FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding six unapproved peptides—BPC‑157, TB‑500, KPV, MOTS‑c, Semax and Epitalon—to the 503A Bulks List. nemosnewsnetwork.com · amgreatness.com · natlawreview.com · uinterview.com · www.phillyvoice.com
[○ 1 SOURCE] More than half of surveyed weight‑loss clinics and medical spas offered compounded GLP‑1 products; 23 compounding facilities were identified, some unlicensed. nam.org
[○ 1 SOURCE] HHS Secretary Robert F. Kennedy Jr. expressed personal enthusiasm for peptides and backed the review of peptide injections. uinterview.com
[○ 1 SOURCE] Bioethicist Dr. Ezekiel Emanuel criticized the FDA panel’s endorsement of the six peptides, saying it may put health at risk. www.phillyvoice.com
[○ 1 SOURCE] Compounded GLP‑1 products remain widely available despite legal prohibitions after the 2025 shortage ended. nam.org
[○ 1 SOURCE] The PCAC vote was narrow and advisory, not automatically changing the legal status of the peptides. natlawreview.com